FXVIEW Goes Global, Sets up a Subsidiary in Saint Vincent and Grenadines
21.6.2021 10:47:00 EEST | Business Wire | Press release
Fxview, Cyprus based forex and CFDs financial services company, announced today that it has set up an offshore subsidiary in St Vincent & The Grenadines. Until now, Fxview has been operating with its EU licenses from Cyprus.
Charlgate SVG LLC, their locally incorporated arm will ensure the expansion of products and services on Fxview’s platforms. It will also allow them to offer regulated forex and CFDs trading services to traders around the globe.
Fxview operates in Europe with its multiple European Licenses and is already an established brand in the EU market. Earlier this month, the company was acquired by a global FinTech leader Finvasia Group.
“We anticipate that many more traders will join our platform where we plan to offer additional products and services like research & analysis, higher leverage, sophisticated trading tools, social trading, MAM / PAMM services, affiliate programs, loyalty reward programs and more,” said Rahul Bansal, Director of Charlgate SVG LLC.
“We have been successfully operating uninterrupted in the trading industry for more than a decade, and one of our missions has always been to grow our regulatory framework,” said Sarvjeet Virk, Managing Director of FINVASIA Group.
“The offshore entity is a key milestone for Fxivew. This will allow our existing and new clients to take full advantage of our innovative ecosystem ranging from state-of-the-art platforms & tools, lightning-fast execution, excellent trading conditions and stellar customer support” he further added.
About Fxview
Fxview is a brand owned and operated by Charlgate Ltd (a Finvasia Group Company) with its headquarters in Limassol Cyprus. Charlgate Ltd operates under the European Markets in Financial Instruments Directive (MiFid) and is regulated by CySec under license 367/18 since 2018 and is a Member of the Investor Compensation Fund (ICF).
Charlgate Ltd is also registered with the UK Financial Conduct Authority – FCA ( 850138), the German Federal Financial Supervisory Authority – BaFin ( 157125), the French Autorité de Contrôle Prudentiel et de Résolution – ACPR ( 85051), the Italian Commissione Nazionale per le Società e la Borsa – CONSOB ( 5151), the Spanish Comisión Nacional de Mercado de Valores – CNVM ( 4892), the Norway Finanstilsynet – ( FT00118545).
Know more: https://fxview.com/
About FINVASIA Group
FINVASIA is a multi-disciplinary, multinational organisation that invests in technology-oriented business and products. It is registered with a gamut of regulatory bodies across the world in various capacities. Finvasia (along with its subsidiaries and sister concerns) is registered with SEC, USA (152771 ), Reserve Bank of India as an NBFC, National Stock Exchange of India as Professional Clearing member(M51912), Bombay Stock Exchange(4043), Multi Commodity Exchange of India(55135) and NCDEX as Trading Member(01259), Association of Mutual Funds of India(103331) and CDSL as Depository Participant(12084300).
Know more: https://finvasia.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210621005285/en/
Contact information
Media:
Ms. Sandeep Samra
media@fxview.com
+35725251100
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
